Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 556,997
  • Shares Outstanding, K 58,817
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -32,140 K
  • 60-Month Beta 3.00
  • Price/Sales 34.53
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CRIS with:

Options Overview

Details
  • Implied Volatility 126.39%
  • Historical Volatility 64.40%
  • IV Percentile 7%
  • IV Rank 6.14%
  • IV High 1,119.79% on 06/05/20
  • IV Low 61.45% on 04/17/20
  • Put/Call Vol Ratio 0.33
  • Today's Volume 274
  • Volume Avg (30-Day) 2,599
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 34,562
  • Open Int (30-Day) 45,991

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.26
  • Growth Rate Est. (year over year) +73.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.25 +14.79%
on 03/05/21
12.29 -22.95%
on 02/11/21
-0.78 (-7.61%)
since 02/05/21
3-Month
1.09 +768.81%
on 12/07/20
13.44 -29.54%
on 01/19/21
+7.59 (+403.72%)
since 12/04/20
52-Week
0.62 +1,427.42%
on 04/07/20
13.44 -29.54%
on 01/19/21
+8.19 (+639.84%)
since 03/05/20

Most Recent Stories

More News
Curis to Present at H.C. Wainwright & Co. Global Life Sciences Conference

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that , President and Chief Executive...

CRIS : 9.47 (+3.72%)
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO

Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO

ADMA : 2.09 (-6.28%)
ARNA : 73.57 (+2.88%)
BDSI : 4.05 (+0.75%)
CRIS : 9.47 (+3.72%)
RGLS : 1.3000 (+13.04%)
NEPT : 1.4100 (+0.71%)
NEPT.TO : 1.78 (+0.56%)
Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that , President and Chief Executive...

CRIS : 9.47 (+3.72%)
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been...

CRIS : 9.47 (+3.72%)
Curis Announces Initiation of Investigator-Sponsored Phase 2 LUCAS Study of CA-4948 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate-Risk Myelodysplastic Syndromes

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the initiation of a Phase 2 investigator-sponsored...

CRIS : 9.47 (+3.72%)
Thinking about buying stock in GameStop, AMC Entertainment, Novavax, Riot Blockchain, or Curis?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GME, AMC, NVAX, RIOT, and CRIS.

CRIS : 9.47 (+3.72%)
NVAX : 174.84 (+10.59%)
RIOT : 40.30 (-9.01%)
AMC : 8.05 (+0.25%)
GME : 137.74 (+4.07%)
Curis to Present at B. Riley Securities Virtual Oncology Investor Conference

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that , President and Chief Executive...

CRIS : 9.47 (+3.72%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on , the independent Compensation...

CRIS : 9.47 (+3.72%)
Curis to Present at H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference

, /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that , President and Chief Executive...

CRIS : 9.47 (+3.72%)
CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(R) technology...

CTMX : 7.78 (+2.37%)
CARA : 18.09 (+0.06%)
CRIS : 9.47 (+3.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 11.21
2nd Resistance Point 10.38
1st Resistance Point 9.92
Last Price 9.47
1st Support Level 8.63
2nd Support Level 7.80
3rd Support Level 7.34

See More

52-Week High 13.44
Last Price 9.47
Fibonacci 61.8% 8.54
Fibonacci 50% 7.03
Fibonacci 38.2% 5.52
52-Week Low 0.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar